Trial Profile
Randomized controlled double blind trial to study Safety and Efficaccy of itolizumab (antiCD6) in Moderate-to-Severe Psoriasis.
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 14 Oct 2020
Price :
$35
*
At a glance
- Drugs Itolizumab (Primary)
- Indications Psoriasis
- Focus Therapeutic Use
- 29 Aug 2016 New trial record